Waddell & Reed Financial’s Catheter Precision VTAK Stock Holding History

Waddell & Reed Financial’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$3.28M	–	555
2018 Q3	$3.28M	Buy	+1	New	+$4.54M	0.01%	504

Other funds holding VTAK

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Waddell & Reed Financial's VTAK Position: Q4 2018 in Review

Waddell & Reed Financial sold out of Catheter Precision (VTAK) in Q4 2018, closing a stake of 1 share — an estimated $3.28M sold.

Waddell & Reed Financial first reported a position in VTAK in Q3 2018 and held it in 1 quarter. The position peaked at $3.28M in Q3 2018. 10 funds tracked by Wall St. Rank hold VTAK as of Q4 2018.

Waddell & Reed Financial reported no remaining Catheter Precision position as of Q4 2018 after selling out during the quarter.
Waddell & Reed Financial sold 1 Catheter Precision share in Q4 2018, an estimated $3.28M.
Waddell & Reed Financial first reported a position in Catheter Precision in Q3 2018 and held it in 1 quarter.
Waddell & Reed Financial's Catheter Precision position peaked at $3.28M in Q3 2018.
10 funds tracked by Wall St. Rank held Catheter Precision as of Q4 2018.

Based on Waddell & Reed Financial's 13F filing for Q4 2018, filed 14 Feb 2019.